Clinical and Safety Evaluation of Continuously Infused Ceftolozane/Tazobactam in the Outpatient Setting.

Bruce M JonesKathryn HuelferChristopher M Bland

Published in: Open forum infectious diseases (2020)

Ceftolozane/tazobactam delivered as a continuous infusion may be a safe, effective, and convenient way to treat infections caused by P aeruginosa. This novel treatment regimen can be an option for patients to avoid hospital admission or discharge to complete therapy as an outpatient.

Keyphrases

gram negative
end stage renal disease
ejection fraction
newly diagnosed
healthcare
prognostic factors
low dose
peritoneal dialysis
patient reported outcomes
adverse drug